# Ultragenyx Pharmaceutical Inc. Agrees to Sell Fayuvi Voucher for $203 Million

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/31861
Published: 2026-10-14T13:55:28.000Z
Updated: 2026-10-14T13:55:28.000Z
Section: Business

> The priority review voucher was received in connection with Fayuvi’s approval in September. The therapy is also known as rebisufligene etisparvovec.

Ultragenyx Pharmaceutical Inc. agreed to sell a U.S. Food and Drug Administration (FDA) priority review voucher for $203 million. The voucher was received in connection with the September approval of Fayuvi, a rare disease gene therapy also known as rebisufligene etisparvovec.